FDA ex­perts unan­i­mous­ly en­dorse Am­gen’s biosim­i­lar of Ab­b­Vie’s $14B fran­chise drug

An FDA pan­el of­fered a clear en­dorse­ment of Am­gen’s fran­chise-bust­ing biosim­i­lar of Ab­b­Vie’s $14 bil­lion bi­o­log­ic Hu­mi­ra.

The vote was unan­i­mous in fa­vor of an …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.